- Home
- PHVS
PHVS
Pharvaris N.V.
as 12-26-2024 4:00pm EST
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .
| Founded: | 2015 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.0B | IPO Year: | 2021 |
| Target Price: | $40.60 | AVG Volume (30 days): | 97.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.37 - $33.00 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Pharvaris N.V. News
PHVS Breaking Stock News: Dive into PHVS Ticker-Specific Updates for Smart Investing
TipRanks
20 days ago
Pharvaris price target lowered to $46 from $50 at JMP Securities
GlobeNewswire
a month ago
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
GlobeNewswire
a month ago
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
GlobeNewswire
2 months ago
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
GlobeNewswire
2 months ago
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
GlobeNewswire
2 months ago
Pharvaris to Host Virtual Investor Event on October 23, 2024
GlobeNewswire
3 months ago
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
MT Newswires
3 months ago
JonesTrading Initiates Coverage on Pharvaris With Buy Rating, $46 Price Target
Compare PHVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHVS Pharvaris N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.